This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ nialamide,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Depression: Nialamide is primarily prescribed for the treatment of depression. It works by inhibiting the activity of monoamine oxidase, an enzyme that breaks down neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, nialamide increases the levels of these neurotransmitters, which are associated with mood regulation, thereby alleviating depressive symptoms.

  2. Other Mood Disorders: In addition to depression, nialamide may also be used to treat other mood disorders, such as bipolar disorder or dysthymia, under the supervision of a healthcare professional. Its mechanism of action in increasing neurotransmitter levels can help stabilize mood and improve symptoms in these conditions.

  3. Anxiety Disorders: Some studies suggest that MAOIs like nialamide may be effective in treating certain anxiety disorders, such as social anxiety disorder or panic disorder. By modulating neurotransmitter levels in the brain, nialamide may help reduce anxiety symptoms and improve overall functioning.

  4. Obsessive-Compulsive Disorder (OCD): Nialamide and other MAOIs have been investigated as potential treatments for OCD, although selective serotonin reuptake inhibitors (SSRIs) are typically preferred as first-line agents for this condition. MAOIs may be considered in cases where SSRIs are ineffective or not tolerated.

  5. Post-Traumatic Stress Disorder (PTSD): While there is limited research on the use of nialamide specifically for PTSD, MAOIs in general have been explored as potential treatments for this condition. By modulating neurotransmitter levels associated with stress and arousal, nialamide may have some utility in managing symptoms of PTSD.

  6. Neurological Disorders: Some studies have suggested that MAOIs like nialamide may have neuroprotective effects and could potentially be beneficial in neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease. However, more research is needed in this area to establish their efficacy and safety.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of nialamide,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by nialamide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Dorea genus Decreases
0 1 Roseburia genus Decreases
0 1 Clostridioides genus Decreases
0 1 Collinsella genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Clostridium genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
1 0 Clostridioides difficile species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Collinsella aerofaciens species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Clostridium perfringens species Decreases
1 0 [Ruminococcus] torques species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of nialamide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.5 0.5
Age-Related Macular Degeneration and Glaucoma 1.1 1.1
Allergic Rhinitis (Hay Fever) 0.8 0.8
Allergies 2 0.2 9
Allergy to milk products 0.5 0.5
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 1.1 1.4 -0.27
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.6
Ankylosing spondylitis 0.9 0.9
Anorexia Nervosa 0.2 0.7 -2.5
Antiphospholipid syndrome (APS) 0.6 0.6
Asthma 1.3 0.5 1.6
Atherosclerosis 0.3 1.3 -3.33
Atrial fibrillation 0.6 0.6
Autism 2.4 1.3 0.85
Autoimmune Disease 0.7 -0.7
Bipolar Disorder 0.2 0.5 -1.5
Brain Trauma 0.3 0.5 -0.67
Cancer (General) 0.7 -0.7
Carcinoma 0.9 0.9 0
Celiac Disease 0.6 0.6 0
Cerebral Palsy 0.2 0.5 -1.5
Chronic Fatigue Syndrome 0.2 1.2 -5
Chronic Kidney Disease 1.5 0.8 0.88
Chronic Lyme 0.6 0.5 0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.5 -0.5
Chronic Urticaria (Hives) 0.2 0.2
Coagulation / Micro clot triggering bacteria 0.5 -0.5
Cognitive Function 0.9 0.7 0.29
Colorectal Cancer 1 1 0
Constipation 0.5 -0.5
Coronary artery disease 0.3 0.5 -0.67
COVID-19 1.4 2.6 -0.86
Crohn's Disease 1.6 1.4 0.14
cystic fibrosis 0.5 -0.5
deep vein thrombosis 0.5 -0.5
Depression 2.1 3.3 -0.57
Eczema 0.2 0.2 0
Endometriosis 0.6 0.5 0.2
Epilepsy 0.5 0.5
erectile dysfunction 0.2 0.2
Fibromyalgia 1.3 0.2 5.5
Functional constipation / chronic idiopathic constipation 0.8 0.8 0
gallstone disease (gsd) 0.8 0.5 0.6
Generalized anxiety disorder 0.2 -0.2
giant cell arteritis 0.2 -0.2
Gout 0.2 -0.2
Graves' disease 0.3 1.4 -3.67
Gulf War Syndrome 0.2 0.2
Hashimoto's thyroiditis 1.1 0 0
Heart Failure 0.8 0.5 0.6
hemorrhagic stroke 0.6 0.6
High Histamine/low DAO 0.9 0.9
hypercholesterolemia (High Cholesterol) 0.2 0.2
Hyperlipidemia (High Blood Fats) 0.3 0.3 0
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 0.9 0.5 0.8
Hypoxia 1 1
IgA nephropathy (IgAN) 0.7 -0.7
Inflammatory Bowel Disease 1.3 1.9 -0.46
Insomnia 0.6 0.5 0.2
Intelligence 0.2 0.2
Intracranial aneurysms 0.3 -0.3
Irritable Bowel Syndrome 1.9 1 0.9
ischemic stroke 0.5 -0.5
Liver Cirrhosis 1.3 1.3 0
Long COVID 0.3 2 -5.67
Low bone mineral density 0.5 -0.5
Lung Cancer 0.6 -0.6
ME/CFS with IBS 0.2 0.6 -2
ME/CFS without IBS 0.2 1.2 -5
Menopause 0.5 -0.5
Metabolic Syndrome 2.2 1.3 0.69
Mood Disorders 1.7 2.1 -0.24
Multiple Sclerosis 1.6 1.5 0.07
myasthenia gravis 0.7 -0.7
neuropathic pain 0.5 -0.5
Neuropathy (all types) 0.5 -0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.6 0.5 2.2
NonCeliac Gluten Sensitivity 0.3 0.3
Obesity 2.8 2.1 0.33
obsessive-compulsive disorder 0.6 0.6 0
Osteoarthritis 0.2 0.2
Osteoporosis 0.7 0.6 0.17
Parkinson's Disease 2.2 1.9 0.16
Polycystic ovary syndrome 0.7 0.7 0
Postural orthostatic tachycardia syndrome 0.2 0.2
Premenstrual dysphoric disorder 0.3 0.3
primary biliary cholangitis 0.6 0.5 0.2
Primary sclerosing cholangitis 0.2 0.2 0
Psoriasis 1.4 0.5 1.8
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.6 1.6 0.63
Rosacea 0 0.7 0
Schizophrenia 0.7 0.7 0
Sjögren syndrome 0.6 -0.6
Sleep Apnea 0.6 0.5 0.2
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Stress / posttraumatic stress disorder 1.3 0.8 0.63
Systemic Lupus Erythematosus 0.2 0.5 -1.5
Tic Disorder 0.9 -0.9
Tourette syndrome 0.6 0.6
Type 1 Diabetes 0.2 0.7 -2.5
Type 2 Diabetes 2 1.3 0.54
Ulcerative colitis 1 1.3 -0.3
Unhealthy Ageing 1.2 0.5 1.4
Vitiligo 0.2 -0.2

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]